Clinical Trial Update: Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

Phase 2 trial update on lenalidomide monotherapy for myelodysplastic syndromes, reporting efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Celgene Corporation | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED